Conduit Pharmaceuticals (CDT) Competitors $2.27 -0.04 (-1.73%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.32 +0.05 (+2.20%) As of 07/15/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. LSB, TLPH, DWTX, AEON, NLSP, CLRB, CHRO, KPRX, TSBX, and BMRAShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include LakeShore Biopharma (LSB), Talphera (TLPH), Dogwood Therapeutics (DWTX), AEON Biopharma (AEON), NLS Pharmaceutics (NLSP), Cellectar Biosciences (CLRB), Chromocell Therapeutics (CHRO), Kiora Pharmaceuticals (KPRX), Turnstone Biologics (TSBX), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Its Competitors LakeShore Biopharma Talphera Dogwood Therapeutics AEON Biopharma NLS Pharmaceutics Cellectar Biosciences Chromocell Therapeutics Kiora Pharmaceuticals Turnstone Biologics Biomerica Conduit Pharmaceuticals (NASDAQ:CDT) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment. Which has better valuation and earnings, CDT or LSB? Conduit Pharmaceuticals has higher earnings, but lower revenue than LakeShore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$17.80M-$534.480.00LakeShore Biopharma$80.82MN/A-$61.09MN/AN/A Do analysts prefer CDT or LSB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00LakeShore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in CDT or LSB? 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are held by institutional investors. 7.7% of Conduit Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer CDT or LSB? In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than LakeShore Biopharma. MarketBeat recorded 3 mentions for Conduit Pharmaceuticals and 2 mentions for LakeShore Biopharma. LakeShore Biopharma's average media sentiment score of 0.84 beat Conduit Pharmaceuticals' score of 0.48 indicating that LakeShore Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Conduit Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral LakeShore Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CDT or LSB more profitable? Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -435.57% LakeShore Biopharma N/A N/A N/A Which has more risk & volatility, CDT or LSB? Conduit Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. SummaryConduit Pharmaceuticals beats LakeShore Biopharma on 6 of the 10 factors compared between the two stocks. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.84M$2.44B$5.62B$9.30BDividend YieldN/A1.79%4.25%4.03%P/E Ratio0.009.1428.5719.58Price / SalesN/A676.39423.3093.84Price / CashN/A164.3436.0257.93Price / Book-0.034.608.135.54Net Income-$17.80M$30.99M$3.24B$257.73M7 Day Performance-3.81%-1.81%0.16%-0.08%1 Month Performance-1.30%5.73%5.95%8.09%1 Year Performance-99.40%-7.03%26.09%13.02% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit PharmaceuticalsN/A$2.27-1.7%N/A-99.4%$1.84MN/A0.003LSBLakeShore Biopharma0.7381 of 5 stars$0.99-0.4%N/A-76.1%$9.26M$80.82M0.00773Gap DownTLPHTalphera2.3634 of 5 stars$0.46+2.7%$5.00+979.9%-52.5%$9.25M$650K-1.0319DWTXDogwood Therapeutics1.8774 of 5 stars$4.60-4.2%$10.00+117.4%N/A$9.17MN/A-0.255AEONAEON Biopharma2.3986 of 5 stars$0.79-5.5%$360.00+45,371.8%-99.5%$8.95MN/A4.405NLSPNLS PharmaceuticsN/A$2.27-7.0%N/A+973.2%$8.78MN/A0.006CLRBCellectar Biosciences2.5432 of 5 stars$4.80flat$375.00+7,712.5%-93.8%$8.69MN/A-0.2210Positive NewsCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-88.5%$8.69MN/A-1.084Gap UpHigh Trading VolumeKPRXKiora Pharmaceuticals3.1908 of 5 stars$2.81-1.4%$10.00+255.9%-27.9%$8.68MN/A-0.9710TSBXTurnstone Biologics3.3947 of 5 stars$0.37+0.9%$0.45+23.3%-85.8%$8.37M$19.31M-0.1382BMRABiomerica1.508 of 5 stars$3.40+4.0%N/A+4.3%$8.32M$5.41M-1.4760 Related Companies and Tools Related Companies LakeShore Biopharma Alternatives Talphera Alternatives Dogwood Therapeutics Alternatives AEON Biopharma Alternatives NLS Pharmaceutics Alternatives Cellectar Biosciences Alternatives Chromocell Therapeutics Alternatives Kiora Pharmaceuticals Alternatives Turnstone Biologics Alternatives Biomerica Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
